Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06433362
Status:
RECRUITING
Last Update Posted:
2024-05-29
First Post:
2024-05-15
Brief Title:
CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Tianjin Medical University Cancer Institute and Hospital
Study Overview
Official Title:
A Single Arm Open Label Multi-center Study of Mitoxantrone Hydrochloride Liposome With Cyclophosphamide Vincristine Etoposide and Prednisone CMOEP in Treatment-Naive Patients With Peripheral T-Cell Lymphoma
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a prospective single arm multicenter study to evaluate the safety and efficacy of CMOEP in patients with untreated peripheral T-cell lymphoma
Detailed Description:
This is a single-arm open label multi-center clinical study to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome in combination with Cyclophosphamide Vincristine Etoposide and PrednisoneCMOEP in patients with untreated Peripheral T-cell LymphomaMitoxantrone hydrochloride liposome will be given on day 1 at dose of 18 mgm2 and be combined with cyclophosphamide vincristine etoposide and prednisoneEach cycle consists of 21 days A maximum of 6 cycles of therapy are planned
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None